Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Best Stocks: Four New Names, Four New Buys

By

Biotech names have leapt to the top of his week's "10.0 report" and offer 4 new buy ratings.

PrintPRINT
At StateoftheMarkets.com, we focus our attention on the top-rated stocks of the market for a few simple reasons. The top stocks have the best earnings strength. The top stocks have strong fundamentals. The top stocks are also in the top-ranked industry groups. So from our perspective, the top stocks put the odds in your favor before you ever enter a buy order. So, why would anyone invest/trade in anything else?

Listed below are five companies that made our "10.0 Stocks Report" this week.

"10.0 Stocks" for the Week of April 15, 2013:

Company: Phamacyclics Inc (NASDAQ:PCYC)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Strong Buy
Trading Stop: Close Below $73.79



Company: Continental Resources (NYSE:CLR)
Sector: Energy
Industry: Oil & Gas Exploration & Production
Stock Rating: 10.0
Current Rating: Buy
Trading Stop: Close Below $77.69



Company: Arena Pharmaceuticals (NASDAQ:ARNA)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Strong Buy
Trading Stop: Close Below $7.79



Company: Isis Pharmaceuticals (NASDAQ:ISIS)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Accumulate on Pullback toward $18
Trading Stop: Close Below $15.79



Company: Alnylam Pharmaceuticals (NASDAQ:ALNY)
Sector: Health Care
Industry: Biotech
Stock Rating: 10.0
Current Rating: Strong Buy
Trading Stop: Close Below $21.89



The StateoftheMarkets "Top Stock" Rating

The TopStock Rating indicates the combined score of our proprietary Earning Strength and Company Performance models. The rating scale is 0 - 10 with 10 being the highest.

Current Rating

The Current Rating is designed to let readers know what we would do now if we did NOT currently hold the position.
Strong Buy: Our favorite position. We would be willing to buy a full position at current levels.

Buy: We would be willing to buy at current levels.

Accumulate: We would be willing to take a "starter position" (25% - 33% of the full position) at current levels. However, we would not want to buy a full position at the current time and we would look to add to our "starter position" on weakness.

Hold: We prefer to hold our position at the current levels, but we would not be buyers at this time.

Sell: We are not happy with this position and are looking for an exit point.

This story by Dave Moenning originally appeared on StateOfTheMarkets.com.

Below, find some more great content from David Moenning and StateoftheMarkets.com:

It's Just Silliness, Right?

Wake Up and Smell The Breakout!

Where Are Those Bears Anyway?


Follow on Twitter: @StateDave
< Previous
  • 1
Next >
No positions in stocks mentioned.
PrintPRINT
 
Featured Videos

WHAT'S POPULAR IN THE VILLE